Adenosine receptor A1 or Adenosine receptor A2A (depending on which is meant; see below for clarification) (A1AR, A2AAR)

The adenosine receptors, specifically adenosine receptor subtypes A1 and A2A, are G protein-coupled cell surface proteins highly expressed throughout the central nervous system. They mediate many physiological processes by responding to extracellular adenosine levels that rise during metabolic stress. In the brain, adenosine receptor A1 suppresses neuronal excitability, inhibits neurotransmitter release, provides neuroprotection under hypoxic conditions but may also contribute to sedation. Receptor A2A modulates dopamine signaling, especially relevant in basal ganglia circuits involved in movement control; its antagonism has therapeutic benefit in Parkinson’s disease. Both are major targets for stimulants like caffeine—their blockade leads to increased alertness—and they play key roles across neurological diseases including epilepsy, depression, ischemia/stroke recovery, sleep regulation, and neurodegeneration.

Other names

ADORA1P1 purinergic receptor subtype 1ADORA2AP1 purinergic receptor subtype 2a

Drugs targeting these molecules act primarily as: Antagonists—block the action of endogenous adenosine leading to increased neurotransmitter release and stimulation. Example: Caffeine blocks inhibitory effects mediated by these receptors resulting in CNS stimulation. Istradefylline blocks excessive inhibition from overactive striatal pathways in Parkinson’s. Agonists—mimic adenosine effects leading to neuroprotection or suppression of neuronal activity. Example: Some investigational agents aim for neuroprotective effects via selective activation.